Effects of valsartan and enalapril on regression of left ventricular hypertrophy in patients with mild to moderate hypertension: A randomized, double-blind study

Current Therapeutic Research - Clinical and Experimental

Volumn 61, Issue 6, 2000, Pages 331-338

  Nalbantgil, Sanem ^a,b   Yilmaz, Hasan ^a   Gurun, Cemil ^a   Özerkan, Filiz ^a   Nalbantgil, Istemi ^a   Önder, Remzi ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b NONE   (Turkey)

Author keywords

Enalapril; Hypertension; Left ventricular hypertrophy; Valsartan

Indexed keywords

ENALAPRIL; VALSARTAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIURESIS; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; M MODE ECHOCARDIOGRAPHY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 0033917266     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)80002-8     Document Type: Article

References (25)

1. 1. Kannel WB. Left ventricular hypertrophy as a risk factor in arterial hypertension. Eur Heart J. 1992;13(Suppl D):82-88.
2. 2. Laufer E, Jennings GL, Korner PI, et al. Prevalence of cardiac structural and functional abnormalities in untreated primary hypertension. Hypertension. 1989;13:151-162.
3. 3. Tubau JF, Szlachcic J, Braun S, Massie BM. Impaired left ventricular function reserve in hypertensive patients with left ventricular hypertrophy. Hypertension. 1989;14:1-8.
4. 4. Messerli FH, Ketelhut R. Left ventricular hypertrophy - an independent risk factor. J Cardiovasc Pharmacol. 1991;17(Suppl 4):S59-S67.
5. 5. Koren MJ, Devereux RB, Casale DN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;144:345-352.
6. 6. Levy D, Garrison RJ, Savage DD, et al. Prognostic implication of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990; 332:1561-1566.
7. 7. Dahlöf B. Structural cardiovascular changes in essential hypertension studies on the effects of antihypertensive therapy. Blood Press. 1992;1(Suppl 6):1-75.
8. 8. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: A meta-analysis of 109 treatment studies. Am J Hypertens. 1992;5:95-110.
9. 9. Gibbs CR, Beevers DG. Angiotensin receptor antagonism with losartan and the regression of left ventricular hypertrophy. J Hum Hypertens. 1998;12:493-495.
10. 10. Tadesco MA, Ratti G, Aguino D, et al. Effects of losartan on hypertension and left ventricular mass: A long-term study. J Hum Hypertens. 1998;12:505-510.
11. 11. Himmelmann A, Svensson A, Dahlöf B. Losartan in essential hypertension: Effects on blood pressure and left ventricular mass. High Blood Press. 1995;4:242-248.
12. 12. Thurman PA, Kenedi P, Schmidt A, et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation. 1998;98:2037-2047.
13. 13. Devereux RB. Evaluation of cardiac structure and function by echocardiography and other non-invasive techniques. In: Laragh JH, Brenner BME, eds. Hypertension: Pathophysiology, Diagnosis, and Treatment. New York: Raven Press; 1990:1479-1492.
14. 14. Holwerda NS, Fogari R, Angeli P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension, efficacy and safety compared with placebo and enalapril. J Hypertens. 1996;1:1147-1154.
15. 15. Mallion JM, Boutelant S, Chabaux P, et al. Valsartan, a new angiotensin II antagonist, blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril. Blood Press Monit. 1997;2:179-184.
16. 16. Black HR, Graff A, Shute D, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension, efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens. 1997;11:483-489.
17. 17. Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: A double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol. 1997;37:101-107.
18. 18. Bremmer AD, Baur M, Oddou-Stock P, Bodin F. Valsartan: Long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clin Exp Hypertens. 1997;19:1263-1285.
19. 19. Hedner T, Oparil S, Rasmussen K, et al. A comparison of the angiotensin II antagonist valsartan and losartan in the treatment of essential hypertension. Am J Hypertens. 1999;12:414-417.
20. 20. Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther. 1996;60:341-346.
21. 21. Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens. 1998;12:861-868.
22. 22. Hegner G, Faust G, Freytag F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared to hydrochlorothiazide. Eur J Clin Pharmacol. 1997;52:173-177.
23. 23. Cifkova R, Peleska J, Hradec J, et al. Valsartan and atenolol in patients with severe essential hypertension. J Hum Hypertens. 1998;12:563-567.
24. 24. Devereux RB, Dahlof B. Criteria for an informative trial of left ventricular hypertrophy regression. J Hum Hypertens. 1994;8:735-739.
25. 25. Acartürk E, Demir M, Demircan S. Regression of left ventricular hypertrophy with losartan potassium therapy in patients with hypertension. Curr Ther Res. 1998;12:819-825.